SITEMAP
Looking for something in particular?
Pages
Sitemap
Uncategorized
- Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
- Vacancy: Clinical Programme Lead
- Phase 2 Clinical Results for Vaccitech’s Universal Influenza A Vaccine
- New MERS Coronavirus vaccine clinical trial starts in Saudi Arabia
- Vaccitech Oncology Limited enters collaboration with Cancer Research UK to fund a Phase I/IIa clinical trial as first-line NSCLC therapy
- Vaccitech provides update on clinical progress for its two Phase 2 Universal Influenza studies
- Vaccitech to present clinical development of Universal Influenza A Vaccine (VTP-100) in pandemic and seasonal indications at World Vaccine Congress Europe
- Vaccitech Appoints Bill Enright as New Chief Executive Officer
- Vaccitech Appoints Chief Medical Officer to Oversee Development of Growing Clinical Pipeline of T Cell-Inducing Viral Vector Vaccines
- Vaccitech Universal flu vaccine passes Phase 2b clinical development milestones
- ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform
- Vaccitech Awarded BARDA contract valued at $8.6M to conduct Phase II trial for Influenza Vaccine
- Vaccitech receives £6M investment from GeneMatrix and Korea Investment Partners
- Update: INVICTUS Study
- Vaccitech licenses MERS rights to Oxford University
- New UK-China biotech collaboration to develop shingles vaccine
- VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine
- Phase 1 Data on the Vaccitech Prostate Cancer Vaccine Presented at ASCO 2018
- Universal Flu Vaccine Data Presented at NFID 2018
- Flu vaccine Study Recruits First Participants
- Vaccitech secures £20m Series A with GV, OSI and Sequoia China
- World-First NHS Trial For Universal Flu Vaccine
- Vaccitech Launch RIVET Study
- Vaccitech Feature in Jenner Institute Autumn 2016 Newsletter
- OBN Awards 2016: Vaccitech Announced as Finalists
- Dr Steve Chatfield Joins Vaccitech